ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,926.88
-0.23%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Phathom Pharmaceuticals Inc (PHAT)

  7. Phathom Pharmaceuticals Inc (PHAT) Noticias

PHAT

Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PHAT
FechaHoraFuenteTítuloSímboloCompañía
15/05/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual MeetingNASDAQ:PHATPhathom Pharmaceuticals Inc
09/05/202415:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHATPhathom Pharmaceuticals Inc
09/05/202407:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
09/05/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHATPhathom Pharmaceuticals Inc
29/04/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024NASDAQ:PHATPhathom Pharmaceuticals Inc
03/04/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PHATPhathom Pharmaceuticals Inc
26/03/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”NASDAQ:PHATPhathom Pharmaceuticals Inc
07/03/202415:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PHATPhathom Pharmaceuticals Inc
07/03/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHATPhathom Pharmaceuticals Inc
29/02/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024NASDAQ:PHATPhathom Pharmaceuticals Inc
13/02/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial PatientsNASDAQ:PHATPhathom Pharmaceuticals Inc
31/01/202407:00GlobeNewswire Inc.Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:PHATPhathom Pharmaceuticals Inc
22/01/202419:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHATPhathom Pharmaceuticals Inc
14/12/202307:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules CapitalNASDAQ:PHATPhathom Pharmaceuticals Inc
06/12/202307:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERDNASDAQ:PHATPhathom Pharmaceuticals Inc
28/11/202307:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated HeartburnNASDAQ:PHATPhathom Pharmaceuticals Inc
19/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202315:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202307:00GlobeNewswire Inc.Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business UpdatesNASDAQ:PHATPhathom Pharmaceuticals Inc
01/11/202316:50Dow Jones NewsPhathom Pharmaceuticals Gets FDA Approval for Voquezna TreatmentNASDAQ:PHATPhathom Pharmaceuticals Inc
01/11/202316:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in AdultsNASDAQ:PHATPhathom Pharmaceuticals Inc
30/10/202307:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in AdultsNASDAQ:PHATPhathom Pharmaceuticals Inc
25/10/202307:01GlobeNewswire Inc.Phathom Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:PHATPhathom Pharmaceuticals Inc
26/09/202307:01GlobeNewswire Inc.Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERDNASDAQ:PHATPhathom Pharmaceuticals Inc
21/08/202307:00GlobeNewswire Inc.Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug ApplicationNASDAQ:PHATPhathom Pharmaceuticals Inc
10/08/202307:01GlobeNewswire Inc.Phathom Pharmaceuticals Reports Second Quarter 2023 ResultsNASDAQ:PHATPhathom Pharmaceuticals Inc
17/07/202315:02Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:PHATPhathom Pharmaceuticals Inc
15/06/202308:12Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:PHATPhathom Pharmaceuticals Inc
15/06/202308:05Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:PHATPhathom Pharmaceuticals Inc
12/06/202308:04Dow Jones NewsFDA Accepts Phathom Pharmaceuticals' Resubmission for VonoprazanNASDAQ:PHATPhathom Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PHAT

Su Consulta Reciente

LSE
0KCI
Oneok
BIT
P19KD6
BNP Paribas Issuance
BIT
S27200
Societe Generale Effekten
BIT
UB82D3
Unicredit Bank
TSX
PFLS
Picton Mahoney Fortified...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados